Hab Pharma Can India’s CDMOs Lead the Next Biopharma Wave?India’s Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3–3.5 billion today to $22–25 billion by 2035, …
Hab Pharma The Union Budget 2026 signals a strong shift—positioning India beyond generics toward global leadership in biologics and advanced therapies.With increased investments in innovation and …
